TY  - JOUR
AU  - Grau, S.
AU  - Herling, M.
AU  - Mauch, C.
AU  - Galldiks, N.
AU  - Golla, H.
AU  - Schlamann, M.
AU  - Scheel, A. H.
AU  - Celik, E.
AU  - Ruge, M.
AU  - Goldbrunner, R.
TI  - Hirnmetastasen – interdisziplinär zu einer personalisierten BehandlungBrain metastases–Interdisciplinary approach towards a personalized treatment
JO  - Der Chirurg
VL  - 92
IS  - 3
SN  - 1433-0385
CY  - New York
PB  - Springer
M1  - FZJ-2021-01906
SP  - 200 - 209
PY  - 2021
AB  - The incidence, treatment and prognosis of patients with brain metastases have substantially changed during the last decades. While the survival time after diagnosis of cerebral metastases was on average a maximum of 3–6 months only 10 years ago, the survival time could be significantly improved due to novel surgical, radiotherapeutic and systemic treatment modalities. Only a few years ago, the occurrence of brain metastases led to a withdrawal from systemic oncological treatment and the exclusion of drug therapy studies and to a purely palliatively oriented treatment in the sense of whole brain radiation therapy (WBRT) with or without surgery. The increasing availability of targeted and immunomodulatory drugs as well as adapted radio-oncological procedures enable increasingly more personalized treatment approaches. The aim of this review article is to demonstrate the progress and complexity of the treatment of brain metastases in the context of modern comprehensive interdisciplinary concepts.
LB  - PUB:(DE-HGF)16
C6  - 33502584
UR  - <Go to ISI:>//WOS:000612689200002
DO  - DOI:10.1007/s00104-020-01344-y
UR  - https://juser.fz-juelich.de/record/892055
ER  -